Assessment of aspirin response in patients undergoing neuroendovascular treatments: A comparison of five platelet function tests across two platforms

Aspirin is widely used for periprocedural antiplatelet therapy in neuroendovascular procedures; however, variability in patient response poses clinical challenges. This study aimed to assess five platelet function tests on two different platforms: light transmission aggregometry (LTA) using the CN-6000 device and the VerifyNow system, which were utilized to assess patients undergoing neuroendovascular procedures. A total of 124 patients who underwent elective neuroendovascular procedures and received perioperative aspirin-based antiplatelet therapy between September 2020 and December 2023 were retrospectively reviewed. Platelet function was assessed at three time points: before surgery, 1–3 days after surgery, and 1 month following the procedure. The assessments included maximum aggregation (MA) induced by 1 mM arachidonic acid (AA), 10 μM ADP, and 1 μg/mL collagen, as well as collagen-induced platelet aggregation level (CPAL) and aspirin reaction units (ARU). Significant perioperative changes were observed only with 1 mM AA MA, which increased immediately after surgery (p < 0.001) and decreased at 1 month (p = 0.013), while other tests showed no significant differences. Correlation analysis revealed the strongest association between 1 mM AA MA and 1 μg/mL collagen MA (r = 0.65), followed by CPAL (r = 0.62). ARU correlated modestly with LTA-based measures (r ≤ 0.34). Receiver operating characteristic analysis identified CPAL >6.0 and collagen MA > 43.2% as equivalent to AA MA > 20%. In this cohort, perioperative changes were detected by 1 mM AA MA but not by the other platelet function tests, and correlations between VerifyNow ARU and LTA-based measurements were modest. However, the clinical significance of these differences remains to be established. Automated LTA using CN-6000 may offer a practical option for aspirin monitoring in patients undergoing neuroendovascular procedures. Further prospective studies are warranted to validate its clinical utility.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-19
DOI
https://doi.org/10.1371/journal.pone.0363376
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Assessment of aspirin response in patients undergoing neuroendovascular treatments: A comparison of five platelet function tests across two platforms

Yukiko Enomoto, Tasuku Sakayori, Keisuke Kitano, Kenji Shoda et al.
PLoS ONE
Antiplatelet Therapy and Cardiovascular Diseases
article

Assessment of aspirin response in patients undergoing neuroendovascular treatments: A comparison of five platelet function tests across two platforms

Yukiko Enomoto, Tasuku Sakayori, Keisuke Kitano, Kenji Shoda, Daisuke Mizutani, Ryosuke Kikuchi, Ayumu Kanbe, Aki Oka, Yoshihiko Ueno, Miyu Kitagami, Ryosuke Nakanishi
article en

Abstract

Aspirin is widely used for periprocedural antiplatelet therapy in neuroendovascular procedures; however, variability in patient response poses clinical challenges. This study aimed to assess five platelet function tests on two different platforms: light transmission aggregometry (LTA) using the CN-6000 device and the VerifyNow system, which were utilized to assess patients undergoing neuroendovascular procedures. A total of 124 patients who underwent elective neuroendovascular procedures and received perioperative aspirin-based antiplatelet therapy between September 2020 and December 2023 were retrospectively reviewed. Platelet function was assessed at three time points: before surgery, 1–3 days after surgery, and 1 month following the procedure. The assessments included maximum aggregation (MA) induced by 1 mM arachidonic acid (AA), 10 μM ADP, and 1 μg/mL collagen, as well as collagen-induced platelet aggregation level (CPAL) and aspirin reaction units (ARU). Significant perioperative changes were observed only with 1 mM AA MA, which increased immediately after surgery (p < 0.001) and decreased at 1 month (p = 0.013), while other tests showed no significant differences. Correlation analysis revealed the strongest association between 1 mM AA MA and 1 μg/mL collagen MA (r = 0.65), followed by CPAL (r = 0.62). ARU correlated modestly with LTA-based measures (r ≤ 0.34). Receiver operating characteristic analysis identified CPAL >6.0 and collagen MA > 43.2% as equivalent to AA MA > 20%. In this cohort, perioperative changes were detected by 1 mM AA MA but not by the other platelet function tests, and correlations between VerifyNow ARU and LTA-based measurements were modest. However, the clinical significance of these differences remains to be established. Automated LTA using CN-6000 may offer a practical option for aspirin monitoring in patients undergoing neuroendovascular procedures. Further prospective studies are warranted to validate its clinical utility.

PLoS ONEVol. 21(11)
Gifu University Hospital (JP), Tokushima Municipal Hospital (JP), Gifu University (JP), Sysmex (Japan) (JP)
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon